Swiss oncology powerhouse, BeOne Medicines, has emerged as one of 2025’s top performers in a sector often plagued by volatility. Year-to-date, shares have rocketed 75%, outpacing many peers amid renewed investor enthusiasm for oncology innovations. Yet, the stock has retreated 16% from its November peak, trading around $323 per share as broader market jitters cool the rally.
While 2025 has been a phenomenal year for the biotech, 2026 could be even better.
This post originally appeared at Money Morning.